ESR1 and breast cancer: Our current limited data showed that the recurrent rate of LN+ER/PR-Her2+ status breast cancer was about 43.3% and the recurrent rate of LN-ER/PR+Her2- status breast cancer was about 12.9% in 3 years (Table 1).